The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy

Area of Science:

• Neuroscience
• Biochemistry
• Pediatric Neurology

Background:

• Epilepsy affects approximately 5 in 10,000 children annually, with up to one-third experiencing medically refractory cases.
• The mechanistic target of rapamycin (mTOR) pathway is implicated in epilepsy and tuberous sclerosis complex (TSC).
• Current treatments for refractory epilepsy are limited, necessitating novel therapeutic approaches.

Purpose of the Study:

• To explore the potential of mTOR inhibitors in treating medically refractory epilepsy in children, particularly those without TSC.
• To evaluate the efficacy of mTOR inhibitors in cases where resective surgery has been unsuccessful.
• To build upon existing research on mTOR inhibitors in TSC-related epilepsy.

Main Methods:

• Review of existing preclinical and clinical data on mTOR inhibitors (e.g., rapamycin, everolimus) in epilepsy models and patient populations.
• Analysis of genetic findings linking mTOR pathway mutations to conditions like hemimegalencephaly (HME) and focal cortical dysplasias (FCDs).
• Consideration of safety and tolerability data from previous studies.

Main Results:

• Preclinical studies show rapamycin reduces seizure frequency and duration, and improves cell morphology in epilepsy and TSC models.
• Everolimus has demonstrated seizure reduction with acceptable safety and tolerability in clinical settings, primarily in TSC patients.
• Genetic evidence connects mTOR pathway dysregulation to HME and FCDs, conditions strongly associated with refractory epilepsy.

Conclusions:

• mTOR inhibitors represent a promising therapeutic avenue for children with medically refractory non-TSC epilepsy.
• Further clinical investigation is warranted to establish the role of mTOR inhibitors in this patient group, especially post-surgical failure.
• Targeting the mTOR pathway offers a potential strategy to improve seizure control in challenging pediatric epilepsy cases.